Connection
Jill Johnson to Drug Costs
This is a "connection" page, showing publications Jill Johnson has written about Drug Costs.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.801 |
|
|
|
-
King J, McAdam-Marx C, McCaleb R, Davis D, Bemberg GB, Johnson JT. Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan. J Manag Care Spec Pharm. 2019 Jun; 25(6):646-651.
Score: 0.687
-
Johnson JT, Neill KK, Davis DA. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan. J Manag Care Pharm. 2011 Apr; 17(3):200-12.
Score: 0.097
-
West DS, Johnson JT, Hong SH. A 30-month evaluation of the effects on the cost and utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan. J Manag Care Pharm. 2006 Jan-Feb; 12(1):25-32.
Score: 0.017